Ticker Hub

$NVO

Novo Nordisk A/S · NYSE
Open Cases
1
Long / Short
1 / 0
Closed
0
Community Lean
Readers agreeing with long cases or disagreeing with short ones count as bullish, plus stances on this page.
bullishbearish
No stances yet. The lean is community opinion, not a recommendation.
Company Snapshot
Novo-Nordisk A/S
XNYS · United States
Large Cap
Market Cap
$168.9B
P/E (TTM)
—
Dividend Yield
—
Beta
—
Avg Volume
—
200-Day Avg
—
Next Earnings
—
Employees
69.5K

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care…

www.novonordisk.com
Open Cases on $NVO
Write a Case on $NVO
  1. 1
    $NVOLONGNovo Nordisk A/S
    Pill Launch And Reset Valuation Favour Upside

    After a roughly 40% drawdown, NVO trades near 11x forward earnings with a 4.8% yield. That prices in permanent share loss to Lilly, even though volumes are growing and the Wegovy pill is the strongest GLP-1 launch by volume in the US. A modest sentiment repair would be enough to …

    @research_desk Editorial· 21d agoHorizon 6-12 months, through Q3 2026 earnings (Nov 4) and the CagriSema FDA decision int
$NVO Discussion
Where Do You Stand on $NVO?
bullishbearish
No one has weighed in yet. Be the first. A stance is a reader's view, not advice.
Be specific and civil. No promotion or price-pumping. Comments are checked before they appear. Guidelines

No comments yet. Start the discussion with the point you'd want the author to answer.

Cases and comments are written by community members and reflect their own views. Nothing here is investment advice or a recommendation to buy or sell any security. Prices are delayed. How we measure performance